Rhudex arthritis trial on hold after death
This article was originally published in Scrip
Executive Summary
MediGene has put an ongoing Phase I study with rheumatoid arthritis drug candidate RhuDex on hold after one of the healthy volunteers participating in the trial suffered a heart attack and subsequently died.